Abstract Search

A new radiopharmaceutical using the somatostatin analogue octreotide has been developed for use in humans. SARTATE consists of the novel bifunctional chelator, MeCOSar, conjugated to (Tyr3)-octreotate. MeCOSar is a superior chelator for copper over a wide pH range and at room temperature, which allows for SARTATE to be used as an imaging/therapy pair when radiolabelled with copper-64 and copper-67.4Cu-SARTATE was produced by radiola...

0 shares

ea0089b16 | Basic Science | NANETS2022

[212Pb]PSC-PEG2-TOC Therapy for NET Leads to Complete Responses in Mice Bearing SSTR2 Positive Tumors - Comparison to [177Lu]DOTATATE in a Preclinical Model

Schultz Michael K. , Liu Dijie , Li Mengshi , Cagle Brianna S. , Dai Zhiming , Lee Dongyoul , Orcutt Kelly , Sagastume Edwin , Baumhover Nicholas J. , Vance Ivy , Hedt Amos , Menda Yusuf , Johnson Frances L.

Background: Peptide-based targeted alpha-particle radiotherapy has emerged as a promising approach to cancer treatment. 203Pb/212Pb is the only elementally identical isotope pair for this application. Tyr3-Octreotide (TOC) peptide ligands targeting SSTR2 have been widely investigated preclinically and clinically. [177Lu]DOTATATE was approved by the US FDA to treat patients with gastroenteropancreatic neuroendocrine tumors. However, t...

0 shares

Endocrine Abstracts

Optimised production of ⁶⁴Cu-SARTATE for a phase 1 clinical trial

[212Pb]PSC-PEG2-TOC Therapy for NET Leads to Complete Responses in Mice Bearing SSTR2 Positive Tumors - Comparison to [177Lu]DOTATATE in a Preclinical Model

BiosciAbstracts

Endocrine Abstracts

Optimised production of 64Cu-SARTATE for a phase 1 clinical trial

[212Pb]PSC-PEG2-TOC Therapy for NET Leads to Complete Responses in Mice Bearing SSTR2 Positive Tumors - Comparison to [177Lu]DOTATATE in a Preclinical Model

BiosciAbstracts

Optimised production of ⁶⁴Cu-SARTATE for a phase 1 clinical trial